Alibaba Health Information Technology Limited (ALBBY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Alibaba Health Information Technology Limited (ALBBY) trades at $8.00 with AI Score 46/100 (Grade C). Alibaba Health Information Technology Limited (ALBBY) is a leading healthcare platform in China, specializing in pharmaceutical direct sales and e-commerce. Market cap: $6.45B, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for ALBBY: ALBBY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ALBBY against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ALBBY: the 1 perspectives are evenly split.
How is this calculated? →Alibaba Health Information Technology Limited (ALBBY) Healthcare & Pipeline Overview
Alibaba Health Information Technology Limited (ALBBY) operates as a comprehensive healthcare platform in Mainland China and Hong Kong, integrating pharmaceutical sales and digital healthcare services, backed by the vast Alibaba ecosystem, enhancing its market reach and operational efficiency.
What Is the Investment Thesis for ALBBY?
Alibaba Health Information Technology Limited (ALBBY) is well-positioned for growth, supported by its strong market presence in the pharmaceutical and digital healthcare sectors. With a market capitalization of $6.45B and a P/E ratio of 20.1, the company exhibits solid financial health, evidenced by a profit margin of 5.1% and a gross margin of 23.9%. The ongoing digital transformation in healthcare, combined with the increasing adoption of e-commerce in pharmaceuticals, presents significant growth opportunities. The company's extensive product range, including prescription and over-the-counter drugs, positions it strategically to capture market share in the expanding healthcare market, projected to grow substantially in the coming years. However, potential regulatory challenges in the Chinese healthcare sector may pose risks that investors should monitor closely. Overall, Alibaba Health's integration within the Alibaba ecosystem, coupled with its innovative service offerings, serves as a key value driver for sustained growth.
Based on FMP financials and quantitative analysis
ALBBY Key Highlights
- Market cap of $6.45B, reflecting strong investor confidence.
- P/E ratio of 20.1, indicating reasonable valuation relative to earnings.
- Profit margin of 5.1%, showcasing operational efficiency.
- Gross margin of 23.9%, exceeding industry averages.
- Beta of 1.72, indicating higher volatility compared to the market.
Who Are ALBBY's Competitors?
ALBBY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SSSGY Sartorius AG | $43.93 | +0.00% | $15.17B | 51 |
| FSPKF Fisher & Paykel Healthcare Corporation Limited | $22.52 | +0.00% | $13.23B | 51 |
| ERFSF Eurofins Scientific SE | $78.98 | -1.53% | $13.67B | 43 |
| CHJTF CSPC Pharmaceutical Group Limited | $0.98 | +0.00% | $11.18B | 50 |
| ORINF Orion Oyj | $82.75 | +0.00% | $11.66B | 63 |
| ATAI Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company | $4.88 | -5.97% | $1.80B | 68 |
| MEDS TRxADE HEALTH, Inc. | $7.59 | +4.55% | $13.28M | 63 |
| ONC BeOne Medicines Ltd. | $309.46 | +3.97% | $33.07B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ALBBY's Key Strengths?
- Strong brand recognition and trust within the Alibaba ecosystem.
- Diverse product and service offerings catering to various healthcare needs.
- Robust digital infrastructure enabling efficient e-commerce operations.
- Established partnerships with healthcare providers enhancing service delivery.
What Are ALBBY's Weaknesses?
- Dependence on the Chinese market for revenue generation.
- Limited international presence compared to global competitors.
- Potential regulatory challenges affecting operations in the healthcare sector.
What Could Drive ALBBY Stock Higher?
- Expansion of e-commerce healthcare services projected to enhance revenue growth.
- Integration of digital health solutions to improve patient engagement and service delivery.
- Strategic partnerships with healthcare providers to broaden service offerings.
- Increasing demand for preventive healthcare services driving customer acquisition.
- Launch of new health and wellness products aligned with market trends.
What Are the Key Risks for ALBBY?
- Regulatory changes in the Chinese healthcare sector could impact operations.
- Intense competition from domestic and international healthcare providers.
- Economic fluctuations affecting consumer spending on healthcare products.
- Dependence on the Chinese market for revenue generation.
What Are the Growth Opportunities for ALBBY?
- Expansion of E-commerce Healthcare Services: The growth of online healthcare services is projected to reach $150 billion by 2025, driven by increasing consumer preference for convenience and accessibility. Alibaba Health's established e-commerce platform positions it to capitalize on this trend, enhancing its service offerings and expanding its customer base.
- Integration of Digital Health Solutions: The digital health market is anticipated to grow at a CAGR of 27.7%, reaching $660 billion by 2025. Alibaba Health's investment in digital health technologies, including telemedicine and health apps, allows it to diversify its service offerings and improve patient engagement.
- Increasing Demand for Preventive Healthcare: The global preventive healthcare market is expected to grow to $250 billion by 2027. Alibaba Health's comprehensive range of health services, including medical checkups and vaccinations, positions it well to meet this rising demand and enhance its service portfolio.
- Partnerships with Healthcare Providers: Collaborating with hospitals and clinics can expand Alibaba Health's service offerings and market reach. Strategic partnerships can lead to enhanced service integration and improved patient outcomes, driving revenue growth.
- Focus on Health and Wellness Products: The health and wellness market is projected to grow to $1 trillion by 2024. Alibaba Health's diverse product range, including nutritional supplements and health foods, aligns with this trend, allowing the company to capture a larger share of the market.
What Opportunities Does ALBBY Have?
- Growing demand for digital healthcare solutions and e-commerce services.
- Expansion into new geographic markets and service areas.
- Increased focus on preventive healthcare and wellness products.
What Threats Does ALBBY Face?
- Intense competition from both domestic and international players.
- Regulatory changes in the Chinese healthcare landscape.
- Economic fluctuations affecting consumer spending on healthcare products.
What Are ALBBY's Competitive Advantages?
- Strong affiliation with the Alibaba ecosystem, providing access to a vast user base.
- Diverse product offerings that cater to various health needs.
- Established brand recognition in the healthcare sector.
- Innovative digital health solutions enhancing customer engagement.
- Robust logistics and distribution network supporting efficient operations.
What Does ALBBY Do?
Alibaba Health Information Technology Limited, headquartered in Causeway Bay, Hong Kong, is an investment holding company that specializes in the healthcare sector, primarily focusing on pharmaceutical direct sales and e-commerce. Founded as CITIC 21CN Company Limited, the company rebranded to its current name in September 2014, reflecting its strategic alignment with the Alibaba Group. The company operates a robust online platform that offers a diverse range of products, including prescription drugs, over-the-counter medications, nutritional supplements, medical devices, and health-related products. These products are available through its online stores on Tmall.com and offline pharmacy outlets, catering to both business-to-customer and business-to-business segments. Additionally, Alibaba Health provides various healthcare services, such as medical checkups, nucleic acid testing, medical consultations, and vaccinations, accessible through multiple digital channels, including Taobao, Alipay, and its proprietary Dr. Deer APP. This multifaceted approach enables the company to effectively meet the growing healthcare demands of consumers in Mainland China and Hong Kong. The company’s affiliation with Alibaba allows it to leverage a vast user base and advanced digital infrastructure, positioning it competitively within the healthcare market. As a result, Alibaba Health continues to evolve and expand its offerings, aiming to enhance the accessibility and quality of healthcare services in the region.
What Products and Services Does ALBBY Offer?
- Operate an e-commerce platform for pharmaceutical direct sales.
- Provide a wide range of health-related products, including prescription and over-the-counter drugs.
- Offer healthcare services, such as medical consultations and vaccinations.
- Facilitate online sales through Tmall.com and Taobao.
- Engage in the tracking and provision of healthcare-related internet services.
- Manage internet hospitals and provide asset management services.
How Does ALBBY Make Money?
- Revenue generated from pharmaceutical sales through online and offline channels.
- Earnings from healthcare services, including medical consultations and checkups.
- Income from partnerships with healthcare providers and institutions.
- Sales of health-related products, including nutritional supplements and medical devices.
- Fees from digital health services and technology solutions.
What Industry Does ALBBY Operate In?
The healthcare industry, particularly in pharmaceuticals, is experiencing significant growth driven by increasing consumer demand for health products and services. The global pharmaceutical market is projected to reach approximately $1.5 trillion by 2023, with a compound annual growth rate (CAGR) of around 5.8%. Alibaba Health operates within this expanding market, leveraging its e-commerce capabilities to enhance accessibility to healthcare products. The competitive landscape includes key players such as Sartorius AG (SSSGY), Fisher & Paykel Healthcare Corporation Limited (FSPKF), and CSPC Pharmaceutical Group Limited (CHJTF), each vying for market share in a rapidly evolving sector. Alibaba Health's unique position within the Alibaba ecosystem provides it with a competitive advantage, enabling it to reach a broader customer base and streamline operations.
Who Are ALBBY's Key Customers?
- Individual consumers seeking health and wellness products.
- Pharmacies and healthcare providers looking for pharmaceutical supplies.
- Businesses requiring health services for employees.
- E-commerce users on platforms like Tmall and Taobao.
- Patients seeking online medical consultations and health services.
Company Profile
Alibaba Health Information Technology Limited operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Causeway Bay, HK. The company is led by CEO Difan Shen. ALBBY has traded publicly since 2019.
ROE 15%Key Financial Metrics
Return on equity for Alibaba Health Information Technology Limited stands at 15.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 11.3%, showing how much profit it generates from its asset base. ALBBY trades at a trailing price-to-earnings ratio of 20.13, below the Healthcare sector average of ~23x. Its free cash flow yield is 3.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.03 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.0%, the inverse of the P/E and a quick read on earnings relative to price.
ALBBY Valuation & Market Position
With a $6.45B market cap, Alibaba Health Information Technology Limited sits in the mid-cap segment of the market. Relative to its peer group, ALBBY's quantitative score of 46/100 is roughly in line with the peer average of 52/100.
Quarterly Financial Performance: Alibaba Health Information Technology Limited
Revenue for Alibaba Health Information Technology Limited came in at $17.24B during Q1 2026, a 4.3% improvement versus the preceding quarter. The company recorded net income of $657.5M, with diluted EPS of $0.83. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this mid-cap Healthcare company. Across the four most recent quarters, ALBBY averaged $0.91 in diluted EPS.
F-Score 4/9Financial Health
Alibaba Health Information Technology Limited's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 8.54 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Alibaba Health Information Technology Limited revenue of about $35.16B for fiscal 2026, with EPS near $0.00. The estimate reflects 16 contributing analysts.
ALBBY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future performance, indicating a positive outlook from those closest to the business.
- Community sentiment has shifted positively, with discussions highlighting the potential for growth in the healthcare technology sector.
- Increased focus on digital health solutions positions Alibaba Health well amidst rising demand for telehealth and remote patient monitoring.
- Recent partnerships and collaborations have been announced, enhancing their service offerings and market reach.
Bear Case
- Concerns over regulatory scrutiny in the healthcare sector have surfaced, creating uncertainty around operational capabilities and compliance.
- Market sentiment remains cautious, with some community members expressing doubts about the company's ability to scale effectively in a competitive landscape.
- Recent earnings reports have shown mixed results, leading to skepticism about growth sustainability and profitability.
- The broader economic environment poses risks, as potential downturns could affect investment in healthcare technology and consumer spending.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $17.24B | $657M | $0.83 |
| Q3 2025 | $16.52B | $1.25B | $1.57 |
| Q1 2025 | $16.32B | $663M | $0.82 |
| Q4 2024 | $8.16B | $332M | $0.41 |
Based on FMP financials and quantitative analysis
ALBBY Latest News
-
Asian Penny Stock Insights For June 2026
Yahoo! Finance: ALBBY News · Jun 15, 2026
ALBBY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ALBBY.
Price Targets
Wall Street price target analysis for ALBBY.
ALBBY MoonshotScore
What does this score mean?
The MoonshotScore rates ALBBY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Difan Shen
CEO
Difan Shen has extensive experience in the healthcare and technology sectors, having held various leadership roles within Alibaba Group. He holds a degree in Business Administration and has a strong track record in driving digital transformation and strategic initiatives. Under his leadership, Alibaba Health has expanded its service offerings and strengthened its market position.
Track Record: Difan Shen has successfully led Alibaba Health through significant growth phases, enhancing its digital healthcare capabilities and expanding its product range. His strategic vision has positioned the company to capitalize on emerging market trends in the healthcare sector.
Alibaba Health Information Technology Limited ADR Information Unsponsored
An American Depositary Receipt (ADR) represents shares in a foreign company, allowing U.S. investors to trade them on American exchanges. ALBBY is a Level 1 ADR, meaning it is traded over-the-counter and does not require the same level of disclosure as higher-tier ADRs.
- Home Market Ticker: Primary stock exchange and country: Hong Kong Stock Exchange (HKEX), Hong Kong.
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: ALBB
ALBBY OTC Market Information
The OTC Other tier includes stocks that trade on the over-the-counter market but do not meet the listing requirements of major exchanges like NYSE or NASDAQ. These stocks may have less liquidity and transparency compared to those listed on major exchanges.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Lower liquidity can lead to higher volatility and price swings.
- Limited financial disclosures may pose risks regarding transparency.
- Regulatory scrutiny may impact trading and operational activities.
- Review the company’s financial statements and disclosures.
- Assess the competitive landscape and market positioning.
- Monitor regulatory developments in the healthcare sector.
- Evaluate the management team's track record and strategic vision.
- Consider currency risk associated with ADR investments.
- Affiliation with Alibaba Group enhances credibility.
- Established market presence in the healthcare sector.
- Regulatory compliance and operational transparency.
ALBBY Healthcare Stock FAQ
What does Alibaba Health Information Technology Limited do?
Alibaba Health Information Technology Limited operates as a comprehensive healthcare platform, specializing in pharmaceutical direct sales and e-commerce. The company offers a wide range of health-related products, including prescription and over-the-counter drugs, nutritional supplements, and medical devices. It also provides healthcare services such as medical consultations and vaccinations, leveraging its online platforms to enhance accessibility for consumers.
What do analysts say about ALBBY stock?
Analysts recognize Alibaba Health Information Technology Limited as a significant player in the healthcare e-commerce sector, highlighting its strong market position and growth potential. Key valuation metrics indicate a P/E ratio of 20.1, suggesting reasonable valuation relative to earnings. Analysts consider the company's integration within the Alibaba ecosystem a crucial factor for its future growth, particularly as digital healthcare continues to expand.
What are the main risks for ALBBY?
Alibaba Health Information Technology Limited faces several risks, including potential regulatory changes in the Chinese healthcare sector, which could impact its operations and market strategy. Additionally, intense competition from both domestic and international players poses a threat to market share. Economic fluctuations may also affect consumer spending on healthcare products, creating further challenges for the company.
What are the key factors to evaluate for ALBBY?
Alibaba Health Information Technology Limited (ALBBY) holds an AI score of 46/100 (low). P/E: 20.1x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does ALBBY data refresh on this page?
ALBBY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ALBBY's recent stock price performance?
Alibaba Health Information Technology Limited (ALBBY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong brand recognition and trust within the Alibaba ecosystem. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ALBBY overvalued or undervalued right now?
Alibaba Health Information Technology Limited (ALBBY) trades at 20.1x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ALBBY?
Before investing in Alibaba Health Information Technology Limited (ALBBY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data is based on the latest available information and may be subject to change.